Impact of androgen stimulation on BCL2 Overexpressed LNCaP cells

In analyzing transcriptomic data from a clinical trial of neoadjuvant-intensive Androgen Deprivation Therapy, we observed increased mRNA expression of the hallmark antiapoptotic gene BCL2 in the prostate tumors of treated patients versus those of untreated patients. We showed that BCL2 overexpressed LNCaP cells exhibited resistance to enzalutamide, indicating that BCL2-overexpression leads to castration resistance and cellular plasticity.We performed RNA sequencing on BCL2 overexpressed LNCaP cells tretaed with R1881 to determine BCL2 regulated AR signaling and overed that BCL2 overexpression may alter AR-pathway. Overall design: To investigate the function of BCL2 overexpression, we stably overexpressed humna BCL2 in LNCaP cells. We grow the isogenic pairs of cells to R1881 and perfermed RNA sequencing